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The transmissible agent of prion disease consists of prion protein (PrP) in-sheet-rich state (PrPSc) that can replicate its conformation
according to a template-assisted mechanism. This mechanism postulates that the folding pattern of a newly recruited polypeptide
accurately reproduces that of thePrPSc template.Here, three conformationally distinct amyloid stateswereprepared in vitrousingSyrian
hamster recombinant PrP (rPrP) in the absence of cellular cofactors. Surprisingly, no signs of prion infection were found in Syrian
hamsters inoculated with rPrP fibrils that resembled PrPSc, whereas an alternative amyloid state, with a folding pattern different from
that of PrPSc, induced a pathogenic process that led to transmissible prion disease. An atypical proteinase K-resistant, transmissible PrP
form that resembled the structure of the amyloid seeds was observed during a clinically silent stage before authentic PrPSc emerged. The
dynamics between the two forms suggest that atypical proteinase K-resistant PrP (PrPres) gave rise to PrPSc. While no PrPSc was found
in preparations of fibrils using protein misfolding cyclic amplification with beads (PMCAb), rPrP fibrils gave rise to atypical PrPres in
modified PMCAb, suggesting that atypical PrPres was the first product of PrPC misfolding triggered by fibrils. The current work dem-
onstrates that a new mechanism responsible for prion diseases different from the PrPSc-templated or spontaneous conversion of PrPC
intoPrPSc exists. This studyprovides compelling evidence that noninfectious amyloidswith a structure different from that of PrPSc could
lead to transmissible prion disease. This work has numerous implications for understanding the etiology of prion and other neurode-
generative diseases.
Introduction
Prion diseases, or transmissible spongiform encephalopathies,
are fatal neurodegenerative disorders that can arise spontane-
ously and be inherited or acquired through transmission
(Prusiner, 1997). Three general mechanisms have been put for-
ward to explain the diversity in etiology of prion diseases. Spon-
taneous misfolding and aggregation of the normal cellular
isoform of the prion protein (PrP), PrPC, into the disease-related
infectious isoform, PrPSc, is believed to underlie the sporadic
forms of prion diseases (Cohen and Prusiner, 1998). Inherited
prion diseases have been linked to a number of single point mu-
tations, truncation, or octarepeat expansion mutations in the
PRNP gene, withmore than 20 disease-inducingmutations iden-
tified (Prusiner and Scott, 1997; Kong et al., 2004; Jackson et al.,
2009; Sigurdson et al., 2009). In prion diseases acquired through
the transmission of the infectious form, PrPSc, the abnormal con-
formation replicates itself in an autocatalytic manner by recruit-
ing and converting the PrPC of the host. According to this
template-assisted mechanism, the folding pattern of a newly re-
cruited polypeptide chain accurately reproduces that of a PrPSc
template (Cohen and Prusiner, 1998).
The current work suggests that a new mechanism responsible
for the etiology of transmissible prion diseases exists that is dif-
ferent from those of template-assisted conversion and spontane-
ous conversion of PrPC into PrPSc. In the current work, three
conformationally distinct and well defined amyloid states were
prepared in vitro in the absence of any cellular cofactors using
only highly purified full-length Syrian hamster recombinant PrP
(rPrP). Surprisingly, no signs of prion infection were found in
animals inoculatedwith rPrP amyloid state that resembled PrPSc,
whereas an alternative rPrP amyloid state, with a folding pattern
significantly different from that of PrPSc, induced a pathogenic
process that eventually led to transmissible prion disease. Accu-
mulation of atypical, proteinase K (PK)-resistant PrP (atypical
PrPres) with a PK-resistant core that closely resembled that of the
rPrP fibrils preceded authentic PrPSc. While no PrPSc particles
were found in preparations of the rPrP fibrils in serial protein
misfolding cyclic amplification with beads (PMCAb), the rPrP
fibrils produced atypical PrPres in modified PMCAb, proving
their capability to seed misfolding of PrPC and demonstrating
their structural difference with authentic PrPSc. Moreover, am-
plification of both brain-derived and fibril-triggered PMCAb-
derived atypical PrPres was found to be RNA independent,
whereas amplification of PrPSc was RNA dependent. Taken to-
gether, these results indicate that atypical PrPres was the first
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product of PrPCmisfolding triggered by fibrils and that the RNA-
independent structure of atypical PrPres gave rise to structurally
different, RNA-dependent PrPSc.
The new mechanism of prion disease introduced here postu-
lates that structures substantially different from that of PrPSc can
induce transmissible disease. The current study raises great con-
cern that structures which are considered noninfectious could
lead to a transmissible disease. Because pathological changes as-
sociated with diverse neurodegenerative diseases can be induced
or transmitted in a prion-like manner through aggregated forms
of nonprion proteins (for review, see Aguzzi and Rajendran,
2009; Miller, 2009; Frost and Diamond, 2010), the current work
has far-reaching implications.
Materials andMethods
Ethics statement. This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory An-
imals of the National Institutes of Health. The protocol was approved by
the Institutional Animal Care and Use Committee of the University of
Maryland, Baltimore, MD (assurance number A32000-01; permit num-
ber: 0309001).
Expression and purification of rPrP and formation of rPrP fibrils. Syrian
hamster full-length recombinant PrP encompassing residues 23–231was
expressed and purified according to a described previously procedure
(Bocharova et al., 2005a) with minor modifications (Makarava et al.,
2010). Lyophilized rPrP was dissolved in 5 mMHEPES, pH 7.0, immedi-
ately before use. To form fibrils for inoculations, the rPrP stock solution
was supplemented with 50 mM MES, pH 6.0, and 0.5 or 2.0 M guanidine
hydrochloride (GdnHCl) and incubated at 37°C under continuous agi-
tation. Fibrillation in 0.5 M GdnHCl was performed with 0.5 mg/ml rPrP
under 600 rpmhorizontal shaking using aDELFIA plate shaker (Wallac),
while fibrillation in 2 M GdnHCl was performed with 0.25 mg/ml rPrP
under 24 rpm rotation using a Clay Adams Nutator (model 1105).
S-fibrils were formed in 2 MGndCl with 0.5mg/ml rPrP under shaking as
described previously (Makarava and Baskakov, 2008). Amyloid forma-
tion was confirmed by thioflavin T fluorescence assay, epifluorescent
microscopy, and electron microscopy as described previously (Bo-
charova et al., 2005a). Fibrils were dialyzed into 10 mM sodium acetate,
pH 5.0, for analysis or into PBS, pH 7.4, for inoculations. As a control, a
rPrP stock solution was diluted in PBS, pH 7.4, for a final protein con-
centration of 0.5 mg/ml and used for inoculation as normally folded
-rPrP. Conformation of -rPrP was confirmed by circular dichroism.
Fourier transform infrared spectroscopy. Fourier transform infrared
(FTIR) spectroscopy was performed as described previously (Ostap-
chenko et al., 2010). Briefly, rPrP fibrils were dialyzed in 10 mM sodium
acetate, pH 5.0, loaded into a BioATR II cell of a Bruker Tensor 27 FTIR
spectrometer (Bruker Optics), and their infrared spectra were then col-
lected at 2 cm1 resolution. Five hundred twelve scans were averaged for
each fibril species and treated with Opus software (Bruker Optics) to
obtain FTIR second derivative spectra.
Bioassay. For the first passage, weanling Golden Syrian hamsters (all
males) were inoculated intracerebrally with three different rPrP amyloid
states or-rPrP described above (see Expression and purification of rPrP
and formation of rPrP fibrils). Each animal was anesthetized with 2%
O2/4 minimum alveolar concentration (MAC) isoflurane before receiv-
ing 50 l of inoculum. Starting from the third month postinoculation,
hamsters were observed daily for disease. They were killed at 664–723 d
postinoculation without any signs of clinical disease and their brains
were removed aseptically and saved for analysis and second passage. For
the second passage, 10% brain homogenates (BHs) prepared by sonica-
tion in PBS, pH 7.4 (Makarava et al., 2010), were dispersed by an addi-
tional 30 s of sonication immediately before inoculation. Each hamster
received 50l of 10%BH inoculum intracerebrally under 2%O2/4MAC
isoflurane anesthesia. After inoculation, hamsterswere observed daily for
disease using a ‘blind’ scoring protocol.
Proteinase K digestion. Brains were collected aseptically and cut in half
with disposable scalpels. One half was used to prepare 10%BHs in PBS or
conversion buffer as described previously (Makarava et al., 2010), while
the second half was stored at 80°C for future analysis or fixed in for-
malin for histopathology. For the PK digestion of BH in sarcosyl, an
aliquot of 10%BHwasmixedwith an equal volumeof 4% sarcosyl in PBS
supplemented with 50 mM Tris, pH 7.5, and digested with 20 g/ml PK
for 30 min at 37°C with 1000 rpm shaking using a DELFIA plate shaker
(Wallac) placed in 37°C incubator. PK digestion was stopped by adding
SDS sample buffer and heating the samples for 10 min in a boiling water
bath. For PK digestion of recombinant fibrils, fibrils were diluted to 10
g/ml in 1%normal BH (NBH) in conversion buffer supplementedwith
0.25% SDS and digested with 10 or 50 g/ml PK for 1 h at 37°C. After
loading onto NuPAGE 12% Bis-Tris gels and transfer to PVDF mem-
brane, PrP was detected with 3F4 (epitope 109–112), D18 (epitope 133–
157), or SAF-84 (epitope 160–170) antibody, as indicated. Density
profiles for Western blots were generated using WCIF ImageJ software
(National Institutes of Health).
Protein misfolding cyclic amplification with beads. Ten percent NBH
from healthy hamsters was prepared as described previously (Makarava
et al., 2011) and used as a substrate for PMCA with beads (Gonzalez-
Montalban et al., 2011a). For the first round, 10 l of 10% BH from
inoculated animals was added to 90 l of NBH. The standard sonication
program consisted of 30 s sonication pulses delivered at 50% power
efficiency applied every 30min during a 24 h period. For each subsequent
round, 10l of the reaction from the previous roundwere added to 90l
of fresh substrate. Each PMCAb reaction was carried out in the presence
of three 3/32” Teflon beads (McMaster Carr). To analyze production of
PK-resistant PrP material in PMCAb, 10 l of sample were supple-
mented with 5 l of SDS and 5 l of PK to a final concentration of SDS
and PK of 0.25% and 50 g/ml respectively, followed by incubation at
37°C for 1 h. The digestion was terminated by addition of SDS-sample
buffer and heating the samples for 10 min in a boiling water bath. Sam-
ples were loaded onto NuPAGE 12% Bis-Tris gels, transferred to PVDF
membrane, and probed with 3F4 or SAF-84 antibodies.
Protein misfolding cyclic amplification with partially deglycosylated sub-
strate. To produce substrate for protein misfolding cyclic amplification
with partially deglycosylated substrate (dgPMCAb), 10% NBH from
healthy hamsters prepared for PMCAb (see Protein misfolding cyclic
amplification with beads) was treated with peptideN-glycosidase F (PN-
Gase F) (New England BioLabs, glycerol-free) as follows. After preclear-
ance of NBH at 500 g for 2min, 1500 U/ml PNGase F was added to the
supernatant, and the reaction was incubated on a rotator at 37°C for 5 h.
The resulting substrate was used in dgPMCAb using sonication condi-
tions as described for PMCAb. To prepare RNA-depleted normal brain
homogenate, NBH was precleared at 500  g for 2 min, and then 100
/ml RNase A (Sigma, catalog no. R4875) was added to the supernatant
and the reaction was incubated on a rotator at 37°C for 1 h as described
previously (Gonzalez-Montalban et al., 2011b). Lack of RNA in RNA-
depleted NBH was confirmed by RNA analysis in agarose gel.
Histopathological studies. Formalin-fixed brain halves divided at the
midline (right hemisphere), spinal cord, and spleen were processed for
hematoxylin-eosin (H&E) stain as well as for immunohistochemistry for
PrP, using the mouse monoclonal anti-PrP antibody 3F4 (1:1000, Cova-
nce) and anti-glial fibrillar acidic protein (GFAP; 1:3000, Dako). Blocks
were treated in formic acid (96%)before being embedded in paraffin. For
detection of disease-associated PrP, we applied a pretreatment of 30 min
hydrated autoclaving at 121°C followed by 5min in 96% formic acid.We
evaluated all tissues for the presence of inflammation and PrP immuno-
reactivity, and the brain for the presence of spongiform change and de-
gree of gliosis. Degree of spongiform change, neuronal loss, and gliosis
and intensity of PrP immunostaining were semiquantitatively evaluated
(0, none; 1, mild; 2, moderate; 3, severe) in the following anatomical
regions as described previously: frontal cortex, hippocampus, caudate-
putamen, thalamus, brainstem, and cerebellum (Makarava et al., 2010).
Lesion profiles were obtained by averaging scores of spongiform change,
neuronal loss, and gliosis for each anatomical region and animal group.
Conformational stability assay. Ten percent BHswere sonicated for 30 s
at 50% efficiency within Misonix-4000 microplate horn filled with 350
ml of water. Then the samples were diluted 2-fold with conversion buffer
and incubated with various concentrations of GdnHCl in PBS, pH 7.4,
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for 1 h at room temperature. After incubation, all samples were diluted
with nine volumes of 2% sarcosyl in PBS and incubated for additional 1 h
at room temperature. Then, 20 g/ml PK were added to each sample
followed by incubation for 1 h at 37°C with 1000 rpm shaking using a
DELFIA plate shaker (Wallac). The PK digestion was stopped by 2 mM
PMSF, and the samples were precipitated by addition of 4 volumes of
ice-cold acetone and overnight incubation at20°C. The following day,
samples were centrifuged for 30min at 13,000 rpm in anAccuSpinMicro
centrifuge (Fisher Scientific), the supernatants were aspirated, and the
pellets were dried for 30 min at room temperature, dissolved in 1
SDS-loading buffer, denatured by incubation in boiling water bath for 10
min, and loaded onto NuPAGE 12% Bis-Tris gels. After transfer to
PVDF, PrP was detected with 3F4 antibody.
To analyze the conformational stability of rPrP fibrils, dialyzed prep-
arations of fibrils were supplemented with various concentrations of
GdnHCl in 50 mMMES, pH 6.0, incubated for 1 h at room temperature,
and then diluted out of GdnHCl with 1% NBH in conversion buffer
before PK digestion with 2 g/ml PK for 1 h at 37°C. The reaction was
stopped by PMSF, precipitated by acetone, and analyzed byWestern blot
with SAF-84 antibody. Signal intensity of Western blots was measured
using WCIF ImageJ software (National Institute of Health).
Deglycosylation of PrPres. Removal of N-linked glycans was performed
as described previously (Deleault et al., 2008) using glycerol-free PNGase
F and supplied buffers (New England BioLabs). Ten percent BH or dgP-
MCAb product weremixedwith equal volume of 4% sarcosyl in PBS, pH
7.4, digested with 20 g/ml or 50 g/ml PK as described above, deglyco-
sylated following the procedure described previously (Makarava et al.,
2010), and assayed by Western blot with SAF-84 or D18 antibody.
Results
Generating three conformationally distinct amyloid states
Three experimental protocols that produce three well defined
and conformationally distinct amyloid states were employed as
described previously (Makarava and Baskakov, 2008; Sun et al.,
2008; Ostapchenko et al., 2010). Briefly,
rPrP fibrils were formed in 0.5 M GdnHCl
(referred to as 0.5M fibrils) in 2MGdnHCl
under rotation (referred to as 2 M fibrils),
or in 2 MGdnHCl under shaking (referred
to as S-fibrils, Fig. 1A). rPrP expression,
purification, and fibrillation procedures
were conducted in a laboratory that was
never exposed to transmissible spongi-
form encephalopathies (TSEs). In agree-
ment with the previous studies, 0.5 M
fibrils were substantially shorter in length
than the 2 M fibrils (Sun et al., 2008),
whereas S fibrils displayed a characteristic
curvy shape (Fig. 1A) (Makarava and
Baskakov, 2008; Ostapchenko et al.,
2010). The differences in length between
0.5 M and 2 M fibrils were presumably due
to higher intrinsic fragility of the 0.5 M
fibrils (Sun et al., 2008). As judged from
the GdnHCl-induced denaturation assay,
2 M or S fibrils were substantially more
stable than the fibrils produced in 0.5 M
GdnHCl (Fig. 1B). In agreementwith pre-
vious studies that employed FTIR (Ma-
karava and Baskakov, 2008; Ostapchenko
et al., 2010), 0.5 M and 2 M but not S fibrils
were characterized by a large peak at 1663
cm1, which is typically assigned to - or
-turns (Fig. 1C). In S fibrils, the cross-
structure was represented by a peak at
1625 cm1 with a shoulder at 1614 cm1,
whereas in 0.5 M or 2 M fibrils, the cross- structure exhibited two
peaks at 1628 cm1 and 1614 cm1, where the latter is believed to
represent more rigid -sheets than the former. As judged from
electron microscopy, the interface surface between filaments was
greater in 2 M than in 0.5 M or S fibrils (Fig. 1A), consistent with
the larger fraction of rigid -structure in 2 M fibrils as evident
from a predominant peak at 1614 cm1 (Fig. 1C).
Fibrils (0.5 M) seeded formation of atypical PrPres in animals
The three rPrP fibrillar types or rPrP folded into normal-helical
conformation (-rPrP)were inoculated into Syrian hamsters.No
clinical signs were observed in any animal groups until old age
(664–723 d postinoculation), when all animals were killed. How-
ever, six of seven animals inoculated with 0.5 M fibrils showed
atypical, PK-resistant, C-terminal bands of13, 16, and 23 kDa
(designated as atypical PrPres) (Fig. 2B). Atypical PrPres was
immunoreactive with SAF-84 antibody (epitope 160–170), but
not with 3F4 antibody (epitope 109–112) (Fig. 2 A,B). Upon
treatment with PNGase F, the three PK-resistant bands of 23, 16,
and 13 kDa in atypical PrPres merged into a single band of13
kDa, illustrating that these three bands represent diglycosylated,
monoglycosylated, and unglycosylated forms of a single PK-
resistant fragment, respectively (Fig. 2D). This fragment was im-
munoreactive with SAF-84 (epitope 160–170) antibody, but not
withD18 (epitope 133–157) antibody (Fig. 2D). The PK-resistant
core of 0.5 M rPrP fibrils consisted of two major fragments of 12
and 10 kDa (Fig. 2D). As judged from mass spectroscopy and
epitope mapping, the 12 and 10 kDa fragments were previously
found to encompass residues138–231 and152–231, respec-
tively (Bocharova et al., 2005b). Consistent with these studies,
both PK-resistant fragments were immunoreactive with SAF-84
Figure 1. Analysis of rPrP fibrils produced in vitro. A, Negative staining electron microscopy of 0.5 M fibrils (left), 2 M fibrils
(middle), or S fibrils (right). Scale bars, 0.1m. B, Analysis of fibril conformational stability. Western blots (left) and the confor-
mational stability profiles (right) for fibrils subjected to GdnHCl-induced denaturation and treated with PK: 0.5 M fibrils (circles), 2
M fibrils (triangles), S fibrils (squares). C, Analysis of fibril secondary structure using FTIR spectroscopy. Second derivatives of FTIR
spectra for 0.5 M fibrils (thin line), 2 M fibrils (dashed line), or S fibrils (bold line).
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antibody, but only the 12 kDa fragment
reacted with D18 antibody (Fig. 2D). In
summary, as judged from the epitope
mapping, the PK-resistant core of the
atypical PrPres matched the 10 kDa band
of rPrP fibrils and presumably encom-
passed residues152–231. The difference
between PAGE-mobility of the atypical
PrPres and the 10 kDa rPrP fragment was
likely due to a glycosylphosphatidylinosi-
tol (GPI) anchor in the first one.
In addition to atypical PrPres, four of
six animals inoculated with 0.5 M fibrils
showed variable amounts of PK-resistant
material with a band-shift typical for au-
thentic PrPSc that could be detected by
3F4 and the C-terminal antibodies (Fig.
2A). After three serial PMCAb (sPMCAb)
rounds, brain homogenates from all six
animals that were positive for atypical
PrPres showed PrPSc immunoreactive
with 3F4 (Fig. 2C). In contrast, BH from
one animal that lacked atypical PrPres did
not show any detectible PrPSc even after
three sPMCAb rounds.
No animals from the groups inocu-
lated with 2 M fibrils, S-fibrils, or -rPrP
showed atypical PrPres or PrPSc in their
brain material (Fig. 2A,B). Furthermore,
no PK-resistantmaterials were detected in
any animals from these three groups after
three PMCAb rounds (Fig. 2C). In sum-
mary, we concluded that six of seven ani-
mals were infected upon inoculation of 0.5
M fibrils, whereas no signs of prion infection
couldbedetectedupon inoculationof2M fibrils, S-fibrils, or-rPrP.
Transition from atypical PrPres to PrPSc
To test whether the pathogenic process triggered by 0.5 M fibrils
leads to transmissible prion disease, brain material from animals
#3, #4, #5, and #7 was selected for the second passage. BHs from
these animals contained large (animal #3), medium (#7), small
(#5), or undetectable (#4) amounts of PrPSc, but approximately
equal amounts of atypical PrPres. Animals from all four groups
developed clinical signs of prion disease (Fig. 2E). All four groups
showed similar clinical symptoms, including startle response, dif-
ficulty in righting themselves, substantially reduced activity, and
obesity. After the first signs, the clinical disease progressed very
slowly, which resembled the slow progression of disease reported
for two other synthetic strains, SSLOW and LOTSS (Makarava et
al., 2010, 2011).
The incubation time to clinical disease correlatedwell with the
amounts of PrPSc in the inoculums (Fig. 2A,E). The shortest
incubation time (347  7 d) was found for the animal group
inoculated with BH #3, whereas the longest incubation time
(512 82 d) and incomplete attack rate (5 out 7 animals showed
clinical signs) were observed for the group inoculated with BH #4
(Fig. 2A,E). Because the amounts of atypical PrPres in four BHs
were approximately the same, these results suggest that the dif-
ferences in the incubation time and the attack rate were likely
attributed to the differences in the amounts of PrPSc.
The brainmaterials from four animal groupswere analyzed by
Western blot using SAF-84 antibody that detects both atypical
PrPres and PrPSc (Fig. 3). Because of the overlaps between the
diglycosylated and monoglycosylated atypical PrPres with the
monoglycosylated and unglycosylated PrPSc, respectively (Fig.
3C, presented as a schematic diagram), the PK-resistant profiles
of atypical PrPres and PrPSc mixtures consisted of four bands
(Fig. 3A,B). Nevertheless, the relative amounts of atypical PrPres
versus PrPSc could be estimated based on the peak ratios (Fig.
3B). After careful analysis of the individual PK resistant profiles,
several important observations can be made.
First, substantial amounts of atypical PrPres observed in
animals from the first and second passages for up to 665 d
postinoculation indicate that this form is self-replicating and its
replication does not require the assistance of PrPSc (Figs. 2A,B,
3A). Second, the observations that (1) atypical PrPres appeared
before PrPSc, (2) PrPSc was never detected in animals negative for
atypical PrPres, and (3) brain material from animals positive for
atypical PrPres always gave rise to PrPSc during serial transmis-
sion suggested that atypical PrPres was a precursor of PrPSc (Fig.
2A–C). Third, the group inoculated with BH #3 (with the largest
amounts of PrPSc) showed the highest PrPSc/atypical PrPres ratio
when compared to the other three groups. The group inoculated
with BH #4 (with undetectable amounts of PrPSc) showed the
lowest PrPSc/atypical PrPres ratio (Fig. 3A,B). Furthermore, the
PrPSc/atypical PrPres ratiowas variable not only between the four
groups but also within individual groups (Fig. 3A). The greatest
variation was observed for the group inoculated with BH #4.
Significant variations in PrPSc/atypical PrPres ratios at the end of
the first and second passages suggest that the seeding of PrPSc by
Figure 2. Bioassay of rPrP fibrils. A, B, Western blots of brain homogenates from the animals inoculated with 0.5 M fibrils, 2 M
fibrils, S fibrils, or-rPrP and stained with 3F4 (A) or SAF-84 (B) antibody. In A, films were overexposed to emphasize a variation
in the amounts of PrP Sc. Undigested BHs are provided as references. BHs from the animals with numbers in rectangles were used
for the second passage. C, Western blots of products of sPMCAb reactions seededwith BHs from the animals inoculatedwith three
fibril types or-rPrP. sPMCAb consisted of three rounds; 3F4 antibody was used for staining. D, Western blots of brain material
containing atypical PrPres (lanes 1–3) or 0.5 M fibrils produced in vitro (lanes 4–6) and stainedwith SAF-84 or D18 antibodies. BH
in lanes 3was treatedwith PNGase F. The 0.5 M rPrP fibrils in lanes 5were treatedwith 10g/ml and in lanes 4with 50g/ml PK.
Undigested BH and 0.5 M fibrils are provided as references. E, Mean incubation time to diseaseSD (light gray bars) and mean
duration of clinical disease SD (dark gray bars) in four animal groups inoculated with BHs from the animals #3, #4, #5, and #7.
Numbers within light bars show the attack rates within individual groups. At 665 d postinoculation (marked by dashed line) all
remaining animals were killed due to old age and regardless of the disease stage.
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atypical PrPres appeared to be a stochastic event. Fourth, PrPSc
was predominantly diglycosylated, whereas atypical PrPres was
predominantlymonoglycosylated (Figs. 2A,D). This observation
illustrates that these two forms had different preferences in re-
cruiting the three PrPC glycoforms and supports the notion that
the two forms were structurally different. Fifth, accumulation of
atypical PrPres alone was not sufficient for development of clin-
ical disease. In support of this notion, two animals from the
group inoculated with BH #4 that showed large amounts of atyp-
ical PrPres but very little if any PrPSc were asymptomatic (Fig.
3A). Sixth, because atypical PrPres was eventually replaced by
PrPSc (Fig. 3A), PrPSc appears to replicate faster and outcompete
the atypical PrPres.
Serial transmission of 0.5 M fibrils leads to a new disease
phenotype
Histopathological studies of animals from the second passage
revealed characteristic signs of TSE infection, including spongi-
formdegeneration, neuronal loss, reactive astrogliosis, and depo-
sition of disease-associated PrP in the brains without signs of
inflammatory infiltration. Spongiform change, neuronal loss,
and reactive astrogliosis were predominantly found in the thala-
mus and the brainstem followed by caudate-putamen (Fig. 4
A,B). However, they were noted also in the frontal cortex, hip-
pocampus, and, to a lesser extent, in the
cerebellum. A diffuse/synaptic type of im-
munoreactivity was observed in all exam-
ined subregions (Fig. 4B). In addition,
perineuronal deposits were found pre-
dominantly in the thalamus, basal ganglia,
and deeper layers of the cortex (Fig. 4C).
Prominent large plaques and amorphous
deposits were present in the subpial,
periventricular, and periaqueductal sub-
ependymal regions (Fig. 4C). Further-
more, small PrP plaques were observed
around vessels, mainly in the whitematter
of the cerebellum (Fig. 4C). The new
synthetic strain that emerged upon in-
oculation of 0.5 M fibrils will be desig-
nated as S05.
Biochemical properties of S05 PrPSc
were assessed using several assays. While
S05 PrPSc and 263K PrPSc showed very
similar PK resistance (Fig. 5A), S05 PrPSc
was conformationally more stable than
263K PrPSc (Fig. 5B). PNGase treatment
revealed that the size of the PK-resistant
core of S05 PrPSc was slightly shorter than
that of 263K PrPSc (Fig. 5C). Overall, tak-
ing aside strain-specific differences, bio-
chemical assays confirmed that S05 PrPSc
exhibits physical features typical for au-
thentic PrPSc.
Preparation of 0.5 M fibrils lacks any
detectible PrPSc
An alternative to the hypothesis that non-
infectious rPrP fibrils gave rise to PrPSc is
the hypothesis that the preparation of 0.5
M fibrils contains small amounts of PrPSc.
To test whether small amounts of PrPSc
were present in the preparations of 0.5 M
fibrils, we employed sPMCAb protocol capable of detecting sin-
gle PrPSc particles. First, we demonstrated that miniscule
amounts of S05 PrPSc can be efficiently detected by sPMCAb. Ten
percent BHs prepared from clinically ill animals from the second
passage of S05 were diluted in 10-fold serial steps, and then ali-
quots from each dilutionwere used to seed sPMCAb reactions. In
100 l of PMCAb reaction volume, 1010- and 1011-fold diluted
S05 brainmaterial was detected with 100% and 66% success rate,
respectively (Fig. 6A). The reactions seeded with 1012-fold or
higher dilutions were all negative. Five sPMCAb rounds were
sufficient for amplification of the highest dilutions of S05 brain
material to the detectible level. An increase in the number of
sPMCAb rounds did not improve the success rate in the reactions
seeded with highly diluted brain material (Fig. 6A). These results
illustrate that the limiting dilution was reached at 1011-fold dilu-
tion. At 1011-fold dilution there is a 66%chance of finding at least
one PMCAb-active PrPSc particle per 100 l of reaction volume.
This experiment demonstrated that sPMCAb can effectively de-
tect as little as a single S05 PrPSc particle.
In the next series of experiments, sPMCAb was employed to
detect PrPSc in the preparations of 0.5 M rPrP fibrils. Multiple
sPMCAb reactions were seeded with 0.5 M fibrils from two inde-
pendent amyloid preparations. No positive signals were detected
in any reaction after six sPMCAb rounds (Fig. 6B). As judged
Figure 3. Analysis of brain materials from the second passage. A, Western blots of brain material from the animals of second
passage inoculated with BHs #3, #4, #5, and #7 and stained with SAF-84. Two animals marked by asterisks in the group #4 were
asymptomatic up to 665 d postinoculation. The animal marked with ampersand (&) was euthanized at 534 d postinoculation due
to an unrelated health problem.B, PK resistance profiles for individual animals from two groups: those inoculatedwith BH #4 (top
panel) or BH #3 (bottompanel). Four peaks at 33, 23, 16, and 13 kDa represent six PK-resistant bands. C, Schematic representation
of thePK resistanceprofile showingoverlapbetweenatypical PrPres andPrP Sc,where atypical PrPres andPrP Sc are representedby
gray and black boxes, respectively.D, Hypothetical mechanism illustrating genesis of PrP Sc in animals inoculatedwith rPrP fibrils.
During the first passage, rPrP fibrils seeded atypical PrPres, a new transmissible form of PrP capable of self-replicating without
detectible clinical signs. Replication of atypical PrPres occasionally produces PrP Sc in seeding events that appeared to be relatively
rare and stochastic, and are described by a deformed templatingmechanism (Makarava et al., 2009, 2011). PrP Sc replicates faster
than atypical PrPres and eventually replaces its ancestor.
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from the previous experiment, five sPMCAb rounds were sufficient
todetect S05PrPSc at the level of a singleparticle in100l of reaction
volume.To rule out thepossibility that thenegative results indetect-
ingPrPSc in thepreparationsof0.5Mfibrilsweredue toan inhibitory
effect of fibrils on PrPSc amplification, sPMCAb reactions were
seeded with 0.5 M fibrils mixed with 1010-fold diluted S05 brain
material. This dilution was the highest at which 100% sPMCAb re-
actions were positive. Three independent sPMCAb reactions were
conducted, and all were positive (Fig. 6B). This experiment con-
firmed that the presence of rPrP fibrils did not diminish the sensitiv-
ity of detection of S05 PrPSc by sPMCAb. These experiments
revealed that thepreparationsof rPrPamyloid fibrils didnot contain
any PrPSc particles that could be detected by sPMCAb. In our expe-
rience and consistent with the previously published data (Saa et al.,
2006; Makarava et al., 2012), sPMCAb is up to 4000-fold more
sensitive than bioassay. These experiments also showed that 0.5 M
fibrils failed to convert PrPC into PrPSc in sPMCAb if used as a
source of seeds.
Atypical PrPres could be amplified in modified PMCAb using
partially deglycosylated PrPC
While atypical PrPres appeared to represent one of the self-
replicating PrP structures, our numerous attempts to amplify
atypical PrPres in PMCAb failed (data not shown). We hypothe-
sized that the PrPC glycoform ratio in NBH favors PrPSc ampli-
fication but is disadvantageous for atypical PrPres, which is
predominantly monoglycosylated. Indeed, when NBH was pre-
treated with PNGase F (Fig. 7A), atypical PrPres could be readily
amplified (Fig. 7B,C). Pretreatment of NBH with PNGase F did
not fully remove glycosyls but shifted the ratio of PrPC glyco-
forms from predominantly diglycosylated to predominantly
monoglycosylated (Fig. 7A). The PMCAb format that uses
PNGaseF-pretreatedNBHasa substrate is designatedasdgPMCAb.
Notably,much lower amounts of PrPSc was amplified in dgPMCAb
than in standard PMCAb seeded with the same brain material (Fig.
7B). Nevertheless, the amounts of dgPMCAb-produced PrPSc cor-
related well with the amounts of PrPSc seeds in brain material: the
Figure 4. Histopathological analysis. A, Lesion profile (left) and PrP immunopositivity score (right) in hamsters inoculated with BH #3 (squares, red lines). The histopathological profiles for the
second passage of LOTSS-inoculated hamsters (circles, blue lines) are provided as a reference (Makarava et al., 2011). B, Comparison of spongiform changes in the hippocampus, frontal cortex,
thalamus, and cerebellum stained with H&E (top) or anti-PrP 3F4 antibody (bottom) (scale bar, 100m for all panels). C, Plaques in the brain subependymal region stained with H&E and 3F4
antibody (scale bar, 30m), perineuronal PrP immunoreactivity (indicated by a white arrow) in the thalamus (scale bar, 10m), and perivascular PrP plaques (indicated by black arrowheads) in
the cerebellar white matter (scale bar, 10m).
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reactions seeded withmaterial #3 showed themost abundant PrPSc
signal, whereas the reactions seeded with material #4 produced the
least abundant signal (Figs. 2A, 7B). Again, no signs of atypical
PrPresweredetected inPMCAbseededwith the samebrainmaterial
containing atypical PrPres (Fig. 7B,C). These results suggest that (1)
atypical PrPres and PrPSc are two self-replicating states, which com-
pete for a substrate in dgPMCAb, and (2) dgPMCAb favors atypical
PrPres, whereas standard PrPSc had a selective advantage over atyp-
ical PrPres in standard PMCAb (Fig. 7B,C).
While both brain-derived PrPres and dgPMCAb-derived atypi-
cal PrPres were predominantly monoglycosylated, dgPMCAb-
derived PrPres displayed two PK-resistant unglycosylated bands
instead of the one in brain-derived PrPres (Fig. 7B,D). These two
bandswere produced as a result of PK cleavage at two closely located
sites.When dgPMCAb-derived PrPres was treated with higher con-
centration of PK, only a single unglycosylated band similar in size to
unglycosylated brain-derived PrPres was observed (Fig. 7C). In fact,
0.5 M fibrils, too, displayed two PK-digestion sites at a low PK con-
centration and a single site at high PK concentration (Fig. 2D).
Fibrils (0.5 M) triggered atypical PrPres in dgPMCAb
To test whether 0.5 M fibrils can trigger atypical PrPres in vitro,
serial dgPMCAb was seeded with fibrils. Remarkably, the reac-
tions seeded with 0.5 M fibrils produced the same PK-resistant
band pattern as those observed in dgPMCAb seeded with brain
material containing atypical PrPres (Fig. 7B,E). We performed
numerous dgPMCA reactions using several independent prepa-
rations of 0.5 M fibrils and several preparations of PNGase
F-treated NBH substrate. In all experiments, 0.5 M fibril-induced
formation of atypical PrPres was robust. The PK-resistant band
patterns produced by 0.5 M fibrils and brain-derived atypical
PrPres in dgPMCAbwere always remarkably similar if not identical.
No PrPres bands were observed in nonseeded serial dgPMCAb re-
actions or serial dgPMCAb reactions seeded with hamster rPrP
S-fibrils or fibrils produced from full-length mouse rPrP (Fig. 7B).
These results illustrated that the process of inducing atypical PrPres
in dgPMCAb was species specific and 0.5 M fibril structure specific.
Most important, these results supported the hypothesis that 0.5 M
fibrils gave rise to atypical PrPres in animals and that 0.5M fibrils and
atypical PrPres are structurally very similar.
The attempts to use 0.5 M fibril-induced atypical PrPres to
seed PrPSc in standard sPMCAb failed, pointing out that authen-
tic PrPSc was still absent in dgPMCA products of rPrP fibrils, nor
was it generated in sPMCAb. The fact that PrPSc was observed in
dgPMCAb products of amplification of brain-derived atypical
PrPres (Fig. 7B) can be explained by the fact that PrPSc was al-
ready present in those brains in small amounts (Fig. 2A).
Amplification of atypical PrPres is RNA independent,
whereas amplification of PrPSc is RNA dependent
Successful amplification of atypical PrPres in gdPMCA seeded
with 0.5 M fibrils pointed to the fact that atypical PrPres was the
first product of PrPCmisfolding triggered by fibrils. Formation of
atypical PrPres accomplishes an important step in triggering
pathogenic process: switching from rPrP to PrPC, a GPI-
anchored protein with complex glycosylation. The failure to pro-
duce PrPSc in PMCAb upon seeding with dgPMCAb-derived
atypical PrPres supports the idea that atypical PrPres and PrPSc
are structurally different.
Structural differences between atypical PrPres and PrPSc
could be highlighted by the differences in RNA dependency of
their amplification. Previous studies established that amplifica-
tion of hamster-adapted scrapie strains in PMCA was RNA de-
pendent (Deleault et al., 2003, 2007, 2010). Two experimental
formats were used here to test the effect of RNA. In the first format,
serially diluted S05 materials containing atypical PrPres and PrPSc
were used to seed PMCAb or dgPMCAb reactions conducted in
Figure 5. Analysis of S05 PrP Sc biochemical features.A, Analysis of PK-resistance. BHs fromS05-
or263K-inoculatedanimalswere treatedwith increasingconcentrationsofglycerol-freeproteinaseK
(Sigma, catalogno. P6556) in thepresenceof 0.25%SDS for 1hat 37°C. BH fromthe secondpassage
of S05was used.B, Analysis of PrP Sc conformational stability. One percent BHs from animals inocu-
latedwith S05 or 263Kwere incubatedwith increasing concentrations of GdnHCl from 0.4 to 6 M for
1 h, as indicated, then diluted out of GdnHCl, equilibrated for 1 h at room temperature, and digested
with 20g/ml PK.Undigestedbrainmaterial exposed to 0.4MGdnHCl is provided as a reference. BH
from the second passage of S05was used. C, Analysis of a size of PrP Sc PK-resistant core. Two or one
percentBHsfromthefirst (lane2)orsecond(lane3)passagesofS05, respectively, treatedwithPKand
PNGaseFandanalyzedbyWesternblot. BHs fromtheSSLOW-inoculated (lane1)or263K-inoculated
animals (lane4)are shownas references.White line indicates thecenterof S05unglycosylatedPrP Sc.
Western blotswere stainedwith 3F4 in all experiments.
Figure 6. Preparations of 0.5 M fibrils have no detectible PrP Sc.A, S05 brainmaterialwas serially
diluted to up to 1013-fold, and each dilution was subjected to five (top) or six rounds (bottom) of
sPMCAb. Representative results are shown on Western blot stained with 3F4 antibody. B, sPMCAb
reactionswereseededwith0.5MrPrP fibrils (lanes8–13),10 10-folddilutedS05brainmaterial (lanes
2–4), or 0.5M fibrils and1010-folddilutedS05brainmaterial (lanes5–7); then six roundsof sPMCAb
were conducted for each condition. The final concentrationof 0.5M fibrils in sPMCAb reactionwas2.5
g/ml. Brains from clinically ill animals from S05 second passage were used for all experiments.
Undigested 10%NBH is provided as a reference.Western blotswere stainedwith 3F4.
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NBH or RNA-depleted NBH. In PMCAb
(that selectively amplifies PrPSc), the ampli-
fication of S05 PrPSc was observed only in
NBH but not in RNA-depleted NBH (Fig.
8A). The signal detected in RNA-depleted
NBH was simply due to seed dilution (Fig.
8A). IndgPMCAb, amplificationof atypical
PrPres was observed in both NBH and
RNA-depletedNBH,whereas robust ampli-
fication of PrPSc was seen only inNBH(Fig.
8B). RNA depletion substantially reduced
the efficiency of PrPSc amplification.
In an alternative format, dgPMCAb re-
actions were seeded with S05 materials
containing atypical PrPres and PrPSc, and
then four serial rounds were performed in
NBH or RNA-depleted NBH (Fig. 8C).
While atypical PrPres was steadily ampli-
fied in both conditions, PrPSc could be
only amplified in NBH containing RNA
(Fig. 8C). Remarkably, just like brain-
derived atypical PrPres, 0.5 M fibril-
derived atypical PrPres could be also
amplified equally well in the presence or
absence of RNA (Fig. 8D). In summary,
rPrP fibrils that were produced in the ab-
sence of RNA triggered in dgPMCA for-
mation of PrPres, which was also able to
amplify in the absence of RNA. Brain-
derived atypical PrPres was RNA inde-
pendent as well, while S05 PrPSc was RNA
dependent, a feature typical for hamster
prion strains.
Discussion
The current studies demonstrated that
transmissible prion disease could be in-
duced by rPrP fibrils with a structure dif-
ferent from that of PrPSc. A long, clinically
silent stage accompanied by accumulation
of atypical PrPres preceded development
of clinical disease. Several lines of evidence suggested that the
molecular mechanism leading to transmissible prion disease was
fundamentally different from the previously known mecha-
nisms, including the template-assisted conversion initiated by
PrPSc or the spontaneous conversion of PrPC into PrPSc. Accord-
ing to the template-assisted conversion mechanism (Cohen and
Prusiner, 1998), the folding pattern of the newly produced PrPSc
accurately reproduces that of the PrPSc template or seeds. In
contrast, in the current studies, prion infection and transmissible
disease emerged upon the inoculation of 0.5 M fibrils with a struc-
ture different from that of PrPSc (Spassov et al., 2006;Wille et al.,
2009; Ostapchenko et al., 2010; Piro et al., 2011).
In previous studies, cellular cofactors including RNA and lip-
ids were required for generating authentic PrPSc structures in
vitro from PrPC or rPrP (Deleault et al., 2007; Wang et al., 2010).
Furthermore, cellular cofactors including RNAs are believed to
be involved in PrPSc replication (Deleault et al., 2003, 2005). In
the currentwork, rPrP fibrils were produced in the absence of any
cofactors. As judged from x-ray and FTIR analyses, the PrP fold-
ing pattern within rPrP fibrils is significantly different from that
of PrPSc (Spassov et al., 2006; Wille et al., 2009; Ostapchenko et
al., 2010). Moreover, application of ultra-sensitive PMCAb,
which is capable of detecting single PrPSc particles, demonstrated
that preparations of 0.5 M rPrP fibrils had no detectible PrPSc.
PMCAb has been very useful for amplification of minuscule
amounts of PrPSc, but when seeded with recombinant fibrils, no
product was generated, suggesting that authentic PrPSc was ab-
sent in the preparations of fibrils. On the other hand, 0.5 M fibrils
produced atypical PrPres in dgPMCA, proving their capacity to
seed misfolding of PrPC and demonstrating their structural dif-
ference with authentic PrPSc.
When triggered by structures different from that of PrPSc,
genesis of authentic PrPSc appears to involve at least two major
steps (Fig. 3D). The first step consisted of rPrP fibril-seeded for-
mation of atypical PrPres. Similarities in size and position of the
PK-resistant core suggest that atypical PrPres originated from
that of rPrP fibrils (Fig. 2D). Moreover, 0.5 M fibrils triggered
atypical PrPres in dgPMCAbwith a PK resistance profile identical
to that of brain-derived atypical PrPres. In opposite to PrPSc,
amplification of both brain-derived and fibril-triggered atypical
PrPres was RNA-independent.
The second step, the appearance of PrPSc, can be a result of a
series of stochastic mutations of atypical PrPres structure and
selection of the most favorable conformers that fit well to a par-
Figure7. Amplification of atypical PrPres inmodified PMCAb.A, Analysis of PrP C glycoform composition in NBHor NBH treated
with PNGase F.B, PMCAb or dgPMCAb reactions were seededwith 10 2-fold diluted brainmaterials from animals #2, #3 or #4 (see
Fig. 2A), 0.5 M fibrils (fibr.), S fibrils, or mouse rPrP fibrils and subjected to four serial rounds. The final concentration of rPrP fibril
seeds in all reactions was 2.5g/ml. The fourth round of nonseeded PMCAb or dgPMCAb reactions is shown as control. The film
was overexposed to show minor amounts of PrP Sc amplified in dgPMCAb. C, Serial PMCAb or dgPMCAb reactions seeded with
10 2-fold diluted brain materials from the #4 animals. The reaction products were treated with 50 or 500g/ml PK as indicated.
PMCAb amplified PrP Sc, whereas dgPMCAb amplified atypical PrPres.D, Analysis of dgPMCAb-derived and brain-derived atypical
PrPres fragments before and after PNGase F treatment. A minor amount of deglycosylated PrP Sc marked by an asterisk appeared
as a result of dgPMCAb amplification. E, Serial dgPMCAb reactions seeded with 0.5 M rPrP fibrils or serial dgPMCAb in the absence
of seeds. The final concentration of 0.5 M fibril seeds in the reaction was 2.5g/ml. In B, D, and E, the reaction products were
treatedwith50g/mlPK. For all serial PMCAbordgPMCAb reactions, 10-folddilutionbetween serial roundswasused.AllWestern
blots were stained with SAF-84.
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ticular cellular environment. The transition from atypical PrPres
to PrPSc is quite complicated and poorly understood. While
achievable in the brain of animals over their life span, this tran-
sition may be very hard to simulate in vitro. While PrPC in ham-
ster brain is predominantly diglycosylated, the distribution of
PrPC glycoforms and their ratio vary in different brain regions
and neuronal compartments as well as during neuronal differen-
tiation (DeArmond et al., 1999; Russelakis-Carneiro et al., 2002;
Monnet et al., 2003). dgPMCAb/PMCAbmight not represent the
environment at cellular sites where the transition from atypical
PrPres to PrPSc occurs. Indeed, PrPSc was not generated in serial
PMCAb seededwith 0.5 M fibrils or with atypical PrPres triggered
by fibrils in dgPMCAb. These results strongly supported earlier
conclusions that authentic PrPSc was absent in preparations of
fibrils or in dgPMCAbproducts of fibrils. If the abovemechanism
is correct, PrPSc can be considered as a relatively rare byproduct
of replication of atypical PrPres. Variations in the amounts of
PrPSc within and between animal groups support the hypothesis
of the stochastic nature of the second step. According to the
proposed mechanism, after the first PrPSc particles were formed,
PrPSc can replicate independently of atypical PrPres and eventu-
ally outcompete its ancestor (Fig. 3D). An
alternative hypothesis is that atypical
PrPres represents a low stability, so-called
class III strain that can readilymutate into
a high stability strain upon serial passage.
(Bruce and Dickinson, 1987). However,
considering that the properties of atypical
PrPres are so strikingly different from
those of low or high stability class PrPSc,
this possibility is unlikely.
Formation of PrPSc in seeding events
initiated by atypical PrPres is best de-
scribed by a mechanism designated as
“deformed templating” (Makarava et al.,
2011). According to deformed templat-
ing, daughter fibrils or particles can ac-
quire a folding pattern different from that
of seeds (Makarava et al., 2009). The ob-
servations that atypical PrPres and PrPSc
preferred different PrPC glycoforms as a
substrate and that atypical PrPres was
RNA independent while PrPSc was RNA
dependent support the notion of signifi-
cant structural differences between these
forms. Substantial variation in amounts
of PrPSc at the end of the first passage sug-
gests that the deformed templating events
are relatively rare and stochastic.
The atypical PrPres described here was
very similar to the atypical PrPres found
in patients with sporadic Creutzfeldt-
Jakob disease (Zou et al., 2003), atypical
bovine spongiform encephalopathy (H-
BSE), which is believed to be sporadic in
origin (Biacabe et al., 2007), or ovine
scrapie (Baron et al., 2008). This current
study suggests that atypical PrPres can
replicate in animal brains and that its rep-
lication does not require PrPSc assistance;
therefore, it represents one of the trans-
missible PrP states. In current and previ-
ous studies on synthetic prions (Makarava
et al., 2011), atypical PrPres always preceded PrPSc. No PrPSc was
found in atypical PrPres-negative animals. While accumulation
of atypical PrPres alone was not pathogenic, its replication seems
to represent a silent stage in the genesis of authentic PrPSc. Bear-
ing in mind that much of the public health risk derives from long
silent or asymptomatic stages (Peden et al., 2004; Comoy et al.,
2008), detection of atypical PrPres should not be underestimated
in developing prion detection strategies. This work introduces
the first approach for selective amplification of atypical PrPres in
vitro—dgPMCAb inRNA-depletedNBH. dgPMCAb should be a
useful technique for establishing the relationship between atypi-
cal PrPres and PrPSc in natural TSEs.
The hypothesis that amyloid structures significantly different
from that of PrPSc can trigger transmissible prion diseases has
numerous clinical and epidemiological implications for under-
standing the origin of TSEs, including TSEs that are considered to
be sporadic. The questions of great interest are whether all PrP
amyloid structures are equally active in triggering PrPSc and, if
not, what is the spectrum of non-PrPSc structures capable of
inducing transmissible diseases in wild-type hosts? In contrast to
0.5 M fibrils, inoculations of 2 M fibrils or S fibrils did not lead to
Figure 8. Analysis of RNA dependency of PrP Sc and atypical PrPres amplification. A, B, Analysis of amplification rate of S05
PrP Sc (A) or atypical PrPres (B) in NBHor RNA-depletedNBH [NBH(RNA)].A, S05 10%brainmaterial fromanimal #3was diluted
10-, 30-, 100-, 300-, or 1000-fold as indicated into 10%NBHor RNA-depletedNBH and amplified for one PMCAb round. Dilution of
seeds without amplification is shown as control. B, Brain material from animal #3 was first amplified in dgPMCAb for four serial
rounds, and then dgPMCAb products were diluted 10-, 30-, 100-, 300-, or 1000-fold, as indicated, into 10%NBH or RNA-depleted
NBH and amplified for one dgPMCAb round. Dilution of seeds without amplification is shown as control. C, Serial dgPMCAb
reactions seeded with S05-derived atypical PrPres and conducted in NBH or RNA-depleted NBH. To prepare S05-derived atypical
PrPres, serial dgPMCAb was seeded with 10 3-fold diluted brain materials from animal #3 and subjected to four rounds. Small
amounts of PrP Sc could not be amplified after RNA depletion, whereas atypical PrPres amplifies well in both conditions. D, Serial
dgPMCAb reactions seeded with 0.5 M fibril-derived atypical PrPres and conducted in NBH or RNA-depleted NBH. To prepare 0.5 M
fibril-derived atypical PrPres, serial dgPMCAbwas seededwith 0.5 M fibrils and subjected to four rounds as shown in Figure 7E. The
0.5 M fibril-derived atypical PrPres amplifies equally well in both NBH and RNA-depleted NBH. In all experiments the reaction
products were treated with 50g/ml PK. All Western blots were stained with SAF-84.
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prion infection. Lack of any PrPres material including atypical
PrPres in these two groups suggest these two structures were not
effective in recruiting and/or converting PrPC. Bearing in mind
that all three amyloid states were formed within the same amino
acid sequence, the differences in their pathogenic activity should
be attributed to their individual fibril-specific physical features.
Previous studies on synthetic prions that employed transgenic
mice established a correlation between conformational stability
of rPrP fibrils and the incubation time to disease (Colby et al.,
2009, 2010). Fibrils with low conformational stability were found
to cause the disease within a shorter incubation time when com-
pared to the high stability fibrils (Colby et al., 2009). In addition,
strain-specific conformational stability of PrPSc was proposed as
one of the physical features that control prion amplification rate
and incubation time to disease (Legname et al., 2005;Makarava et
al., 2010; Ayers et al., 2011; Gonzalez-Montalban et al., 2011b).
The current finding that 2 M or S fibrils with a high stability failed
to trigger prion infection strongly support the previously estab-
lished correlation. As evident from FTIR and x-ray diffraction
analyses, the PrP folding patternwithin S fibrils closely resembled
that of PrPSc (Ostapchenko et al., 2010;Wille et al., 2009). Unex-
pectedly, S fibrils failed to trigger prion infection. S fibrils also
failed to trigger atypical PrPres in vitro. These data suggest that
conformational stability of rPrP fibrils appears to bemore impor-
tant for triggering pathogenic process than an apparent structural
similarity between inoculated material and PrPSc. Conforma-
tional stability appears to be linked to the fibril’s mechanical
properties, such as its intrinsic fragility (Baskakov and Breydo,
2007; Sun et al., 2008). One might speculate that 2 M or S fibrils
failed to recruit PrPC because of their low fragmentation rate.
The current studies illustrate that transmissible prion disease
can emerge according to a previously unknown mechanism that
is different from the spontaneous conversion of PrPC to PrPSc or
the template-assisted conversion initiated by authentic PrPSc.
The key features of the new mechanism are: (1) the pathogenic
process is initiated by amyloid structures different from PrPSc;
(2) it is accompanied by a long clinically silent stage; and (3) it is
characterized by the accumulation of atypical transmissible PrP
states that display limited neurotoxicity before PrPSc emerges.
The current work also shows that prion infection can be induced
in wild-type animals by rPrP fibrils produced in vitro in the ab-
sence of any cellular cofactors or PrPSc seeds.
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